Board of Directors

Panbela Therapeutics, Inc.

Michael T. Cullen, MD, MBA
Chairman

Dr. Cullen has served as Executive Chairman of the board and as a director of our Company since September 2015. He resumed responsibilities as President and Chief Executive Officer of the Company in October 2018. Dr. Cullen brings 30 years of pharmaceutical experience to our Company, including expertise in working with development-stage companies in planning, designing and advancing drug candidates from preclinical through clinical development.

Read more

Jennifer K Simpson, Ph.D., MSN, CRNP
President and Chief Executive Officer

Dr. Simpson joined Panbela as President and Chief Executive Officer in July of 2020 and was also appointed as a Director at that time. She brings to the Company more than 12 years’ experience in pharmaceutical executive leadership, global marketing and product commercialization. Most recently Dr. Simpson was the CEO of Delcath (Nasdaq:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancer.

Read more

Art Fratamico, MBA

Mr. Fratamico is a registered pharmacist with over 25 years of experience in the pharmaceutical industry and has been the Chief Business Officer at Galera Therapeutics since January 2017. Prior to joining Galera, Mr. Fratamico served as Chief Business Officer of Vitae Pharmaceuticals until its sale to Allergan.  

Read more

Dan Donovan

Mr. Donovan served as a Director and Chief Business Officer of Cancer Prevention Pharmaceuticals, Inc., until June 2022, bringing his vision of successful development and commercialization methodologies in rare diseases to CPP. Mr. Donovan is also CEO of rareLife Solutions, Inc, a company he co-founded in 2014.

Read more

Jeff Mathiesen

Mr. Mathiesen has served as a director of our Company since September 2015. Mr. Mathiesen has served as Director and Audit Committee Chair of NeuroOne Medical Technologies Corporation, a publicly traded medical technology company providing neuromodulation continuous EEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders, since 2017.

Read more

Jeffrey Jacob

Throughout his career Mr. Jacob has created technology-based startup companies and supported the expansion of existing companies in both the physical and life sciences. Most recently, Mr. Jacob served as CEO at Cancer Prevention Pharmaceuticals, Inc.

Read more

Robert Schemel

Mr. Schemel has served as a director since the September 2015. Mr. Schemel had previously served as a director of SBR since March 2012. Mr. Schemel has over 39 years’ experience in the agriculture industry. From 1973-2005, Mr. Schemel owned and operated a farming operation in Kandiyohi County, Minnesota, building a 5,000-acre operation producing corn, soybeans and sugar beets.

Read more

Panbela Therapeutics Pty Ltd

Michael T. Cullen, M.D., MBA

Dr. Cullen has served as Executive Chairman of the board and as a director of our Company since September 2015. He resumed responsibilities as President and Chief Executive Officer of the Company in October 2018. Dr. Cullen brings 30 years of pharmaceutical experience to our Company, including expertise in working with development-stage companies in planning, designing and advancing drug candidates from preclinical through clinical development.

Read more

David Harle, Ph.D.

Dr Harle has over 25 years of pharmaceutical experience in clinical development, strategic regulatory affairs, pharmacovigilance, QA and business development. He commenced his career at 3M Pharmaceuticals Australia in 1990 and went on to manage the medical department of Knoll Australia. In 1997, he established the Australian office of ICON Clinical Research (a global CRO) and the Asia-Pacific regional office located in Singapore in 1999…

Read more